Sweetch

Name

Sweetch

Legal name

Sweetch Health Ltd.

Website

https://sweetch.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Digital Therapeutics

NAICS

Computer Systems Design and Related Services (54151), Computer Systems Design Services (541512)

SIC

Services-Prepackaged Software (7372), Services-Health Services (8000)

akta.pro primary industry

Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs) (HLALAFAF)

akta.pro secondary industries

Therapeutic Companion Apps (Drug-Device-Digital Combination) (HLACANAH), Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ), DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms (HLACANAM)

Keywords

• Digital therapeutics platform
• Behavioral health technology
• Patient engagement software
• Chronic disease management
• AI-powered health coaching

Headquarters

HQ city

Tel Aviv-yafo

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. B2B Platform Licensing/Subscription: Sweetch provides its platform to enterprise customers (pharma, med devices, payers, providers, pharmacies) who distribute it to their patients. Revenue likely comes from platform licensing fees, potentially tiered based on user volume or features.
2. Virtual Patient Support Programs (PSP): Provides virtual patient support programs for pharmaceutical and medical device companies to improve treatment adherence, retention and engagement of their customers.
3. RPM (Remote Patient Monitoring): Continuous remote patient monitoring with reimbursable data sync and analysis for healthcare providers, generating revenue through healthcare reimbursement mechanisms.

Go-to-market motion2 records

Distribution channels6 records

Marketing channels6 records

Core offering

Sweetch provides a clinically validated Just-in-Time Adaptive Intervention (JITAI) digital therapeutics platform that combines behavioral science with AI and emotional intelligence to deliver hyper-personalized health recommendations. The platform addresses medication adherence, physical activity, weight management, nutrition, sleep, mood, CGM engagement for Type 2 diabetes, remote patient monitoring, PROMS, education, and treatment follow-up. It is offered as a B2B enterprise solution, including white-label deployments, to pharmaceutical companies, medical device manufacturers, payers, healthcare providers, and pharmacies, who deliver it to their patients.

Product overview

Sweetch is a clinically validated Just-In-Time Adaptive AI (JITAI) platform that combines behavioral science with AI and emotional intelligence (EI) to deliver hyper-personalized health recommendations. The platform architecture consists of a core Sweetch Platform that serves as the foundation, with multiple intervention domain modules including Medication Adherence, Physical Activity, Weight Management, Nutrition & Meals, Sleep, and Mood. Additional modules provide Remote Patient Monitoring (RPM), PROMS collection, Education & Content, Gamification, Community Support, and Treatment Follow-Up capabilities. The platform includes specialized solutions for CGM engagement (for Type 2 diabetes), a Digital Health Coach for Diabetes Prevention Programs, Virtual Patient Support Programs (PSP), and a White Label App option. Sweetch addresses multiple chronic conditions including Diabetes, Obesity, Cardiovascular diseases (hypertension, high cholesterol, coronary artery disease, congestive heart failure), Autoimmune conditions, and Oncology, with support for comorbidities and multiple health domains. The platform is offered to healthcare organizations including Pharma, Medical Device manufacturers, Payers, Healthcare Providers, and Pharmacies.

Differentiator

Problem solved

Functional benefit

Products and services

• Sweetch Platform A clinically validated Just-in-Time Adaptive AI (JITAI) platform that combines behavioral science with AI and emotional intelligence to drive long-lasting behavior change and improved health outcomes for individuals with chronic conditions at scale; offered to enterprise healthcare organizations as a white-label or embedded solution.
• CGM Engagement Platform for Type 2 Diabetes AI-powered continuous glucose monitoring engagement platform for Type 2 diabetes that connects with blood glucose monitors and analyzes how meals, activity, and behavior affect blood sugar; designed for use by pharma, device manufacturers, and providers serving T2D patients.
• White Label App White-label version of the Sweetch platform that allows enterprise partners (pharma, payers, providers, device makers) to deploy the technology under their own brand for patient engagement programs.
• Virtual Patient Support Programs (PSP) Virtual patient support program enhancement enabling pharmaceutical companies and medical device companies to deliver automated, hyper-personalized patient support and improve adherence, retention, and engagement.
• Remote Patient Monitoring (RPM) Connected devices and remote patient monitoring capabilities enabling continuous and reimbursable remote patient monitoring with automated data sync and analysis for healthcare providers.
• Management Dashboard Data and insights management dashboard providing actionable insights about patients and populations for healthcare providers, pharmaceutical companies, and payers.

Quantifiable outcome

• 86% patient retention in clinical trial at Johns Hopkins
• +3 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

Partnerships

Three partnerships are on record, tiered flagship and core.

• Grupo Fleury's Saúde iDflagshipStrategic or Co-development Partner · 22 September 2021Strategic partnership to tackle Brazil's chronic disease prevalence, particularly amid the COVID-19 pandemic. Grupo Fleury distributes Sweetch to Brazilian patients through its digital health platform, providing regional market access for Sweetch in Latin America.
• Bayer G4AflagshipGTM or Marketing Partner · 18 November 2020Selected as one of Bayer's Agents of Change for 2020 in their Digital Health Partnerships Program. Bayer G4A provides marketing and partnership support to help digital health innovators scale their solutions, with Sweetch participating to expand its reach in the pharmaceutical digital health ecosystem.
• Johns HopkinscoreStrategic or Co-development PartnerClinical validation partner that conducted a clinical trial demonstrating Sweetch's effectiveness. The trial achieved clinically significant HbA1C reduction, weight loss, and physical activity increase with 86% patient retention. Published in JMIR (Journal of Medical Internet Research).

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Omada Health: US-based digital chronic disease prevention and management platform covering diabetes, hypertension, and behavioral health. Closely comparable to Sweetch as both sell B2B to payers, employers, and providers, deploy AI-driven personalized coaching, and target medication adherence plus lifestyle outcomes.
• Livongo (Teladoc Health): Now part of Teladoc Health, Livongo pioneered AI-powered chronic condition management (diabetes, hypertension, weight, mental health) sold to employers, payers, and providers. Direct functional peer to Sweetch's chronic-condition DTx offering and white-label model.
• Virta Health: Digital health company focused on type 2 diabetes reversal and metabolic health via clinician-supervised, AI-personalized nutrition and behavior change. Comparable to Sweetch's CGM-for-T2D and weight management modules and similar enterprise/payer GTM.
• WellDoc: Developer of FDA-cleared digital therapeutics for diabetes (BlueStar) and other chronic conditions, sold to health plans, providers, and employers. Closely aligned with Sweetch on regulated DTx for diabetes, B2B distribution, and pharma partnerships.
• DarioHealth: Global digital therapeutics company offering AI-driven, data-collected chronic condition management (diabetes, hypertension, musculoskeletal, behavioral) sold to payers, employers, and pharma. Direct peer across conditions, channels, and target buyers.
• Vida Health: Virtual chronic care platform combining AI coaching with human clinicians for diabetes, weight, mental health, and hypertension. Comparable to Sweetch in B2B payer/employer sales, condition coverage, and personalized engagement model.
• Noom: Behavior change platform with strong presence in weight management, diabetes prevention, and chronic condition coaching. Comparable to Sweetch on AI-personalized coaching, employer/payer/B2B sales motion, and mobile-first delivery.
• Sidekick Health: European-originated digital therapeutics company delivering gamified, AI-personalized care for chronic and autoimmune conditions via pharma and payer partnerships. Comparable to Sweetch on DTx modular platform, pharma commercialization, and chronic-condition focus.
• mySugr (Roche): Acquired by Roche, mySugr is a leading diabetes management app with CGM/BGM integration and behavior change features. Direct overlap with Sweetch's CGM-for-T2D module and a notable signal of pharma appetite to acquire in this category.
• Aptar Digital Health (Voluntis): Aptar Pharma's digital health arm (formerly Voluntis) develops FDA-cleared digital therapeutics for chronic conditions, sold to pharma and medtech for companion apps. Comparable to Sweetch on therapeutic companion apps, pharma partnership model, and SaMD regulatory pathway.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/sweetchhealth
• LinkedInil.linkedin.com/company/sweetch
• Facebookfacebook.com/SweetchHealth

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds7 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sweetch